Baxter International Inc. · NYSE:BAX
Baxter International — Baxter's 2022 Investor Conference
10 slides from Baxter International's conference presentation, May 25, 2022
Slide 1: Pharmaceuticals & BioPharma Solutions
PHARMACEUTICALS & BIOPHARMA SOLUTIONS JORGE VASSEUR President, Pharmaceuticals & BPS (Interim)
Slide 2: Forward-Looking Statements
Forward-Looking Statements The presentations being made on May 25, 2022 include forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval and may require additional investment) and results of c
Slide 3: Baxter Pharmaceuticals: Who We Are
Baxter Pharmaceuticals: Who We Are • 80+ year legacy in pharmaceutical injectables • Recognized expert in ready-to-use premixes and complex formulations • Global leader in inhaled anesthesia • Safe and reliable compounding pharmacy services • Quality contract manufacturer leveraging our complex manu
Slide 4: Global Market Expected To Grow ~3% Through 2025
Global Market Expected To Grow ~3% Through 2025 CAGR ~$69B Total Market Dynamics ~3% ~$63B Total Opportunities Drug ~$7B Compounding • Stable or growing demand for complex and ~$6B ~6% differentiated products ~$6B Contract ~$5B Manufacturing ~$0.9B • Shift of care outside the hospital drives increas
Slide 5: Market-Leading Portfolio
Market-Leading Portfolio Specialty Injectables Inhaled Anesthesia Expand portfolio and global reach of differentiated Provide customers robust options from complete and complex products, including opportunities in portfolio of inhaled agents and drive adoption of alternate sites of care and new geog
Slide 6: Refined Strategy To Address Changing Market Dynamics
Refined Strategy To Address Changing Market Dynamics 138 100+ 88 Number of Molecules Today 71 Increase focus on launching higher Rationalized portfolio by eliminating value molecules via complex lower value standard generics formulated drugs and differentiated Claris Injectables delivery platforms A
Slide 7: Strategy To Drive Above-Market Growth Of 3% - 4% Through 2025
Strategy To Drive Above-Market Growth Of 3% - 4% Through 2025 Innovation Market Expansion Operational Efficiency Core Therapies: Geographic Expansion: Drive Efficiencies: • Focus on differentiated and • Expand in targeted markets: • Enhance execution of complex molecules Canada, ANZ, Western develop
Slide 8: Steady Cadence of New Launches Drives Innovation Pipeline
Steady Cadence of New Launches Drives Innovation Pipeline Recent Near Term Future Launches Launches Launches Norepinephrine Frozen Zosyn Differentiated Drug Cardene Insulin (EU) Mag Sulfate 10+ Additional Products Delivery Acetaminophen 3 Additional Premixes Propofol (US) 5+ Additional Products Comp
Slide 9: Pharmaceuticals Summary
Pharmaceuticals Summary • Launching differentiated and complex products with a balanced mix of organic and inorganic investments • Expanding the global reach of our existing portfolio and entering alternate sites of care • Investing in contract manufacturing capacity and compounding efficiency for g
Slide 10: Baxter 2022 Investor Conference
Baxter 2022 Investor Conference Wigs ee,
Baxter International — Baxter's 2022 Investor Conference on 6ix